What is HC Wainwright’s Forecast for DMAC Q1 Earnings?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of DiaMedica Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).

DiaMedica Therapeutics Price Performance

DMAC stock opened at $4.98 on Friday. The stock has a market cap of $212.95 million, a price-to-earnings ratio of -8.89 and a beta of 1.52. The company has a 50 day simple moving average of $5.93 and a 200 day simple moving average of $5.12. DiaMedica Therapeutics has a 1 year low of $2.14 and a 1 year high of $6.82.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. OMERS ADMINISTRATION Corp bought a new stake in DiaMedica Therapeutics during the 4th quarter worth $122,000. Millennium Management LLC boosted its stake in shares of DiaMedica Therapeutics by 151.8% during the fourth quarter. Millennium Management LLC now owns 84,829 shares of the company’s stock valued at $461,000 after purchasing an additional 51,139 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $79,000. 683 Capital Management LLC acquired a new position in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $413,000. Finally, Jane Street Group LLC bought a new position in DiaMedica Therapeutics in the 4th quarter valued at approximately $229,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.